NCT05047536 - KZR-261 in Subjects With Advanced Solid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Advanced/Metastatic Solid Tumor

Interventions

DRUG

KZR-261

KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.

Trial Locations (12)

Fox Chase Cancer Center, Philadelphia

Virginia Cancer Specialists (VCS), Fairfax

Winship Cancer Institute of Emory University, Atlanta

Moffitt Cancer Center, Tampa

Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville, Nashville

University Hospitals - Cleveland Medical Center, Cleveland

Cleveland Clinic, Cleveland

Henry Ford Health System, Detroit

START (South Texas Accelerated Research Therapeutics), San Antonio

Cedars Sinai Medical Center, Los Angeles

University of California Los Angeles, Los Angeles

Fred Hutchinson Cancer Center, Seattle